Clinical trials: Sclerosis
Multiple Sclerosis
Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS
This study will seek to determine the benefits that FES-LE cycling has over cycling alone on walking performance and quality of life in people with multiple sclerosis.
- Trial name
- MSCycling (NCT02606604)
- Testing
- RT 300: Lower Extremity Cycling
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stony Brook University
Multiple Sclerosis
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength…
- Trial name
- NCT02665221
- Testing
- No Treatment Arm, Topical Preparation H arm
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Multiple Sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
- Trial name
- REFLEX (NCT00404352)
- Testing
- RNF
- Where
- 67 sites in Argentina, Australia and 25 more
- Volunteers
- 517 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
ALS
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety and tolerability of RNS60 in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02525471
- Testing
- RNS60
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sabrina Paganoni, M.D.
ALS (Amyotrophic Lateral Sclerosis)
ALS Reversals - Lunasin Regimen
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT02709330
- Testing
- Lunasin Regimen, Historical control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Relapsing Forms of Multiple Sclerosis
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease…
- Trial name
- EPOC (NCT01216072)
- Testing
- Fingolimod, Standard MS DMTs
- Where
- 149 sites in United States, Canada and 1 more
- Volunteers
- 1,053 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS)
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in…
- Trial name
- NurOwn (NCT02017912)
- Testing
- Nurown MSC-NTF cells
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the long-term safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis who were previously randomized, received treatment, and completed the…
- Trial name
- REViVALS-1B (NCT05176093)
- Testing
- Engensis
- Where
- 2 sites in United States, South Korea
- Volunteers
- 8 people
- Sponsor
- Helixmith Co., Ltd.
Multiple Sclerosis
Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses
ACTHAR is a FDA approved drug for MS relapses. The purpose of the study is to examine the efficacy of this agent in improving relapses as measured by advanced MRI and laboratory techniques: 1.
- Trial name
- ACTHAR (NCT03021317)
- Testing
- ACTHar
- Volunteers
- 5 people
- Sponsor
- University of Chicago
Detrusor Muscle Hyperactivity
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
The purpose of this study is to determine the efficacy and safety of a single dose of 750 U of Dysport compared to placebo for the improvement in the daily incontinence episode frequency for each administration mode in subjects…
- Trial name
- NCT01357980
- Testing
- Botulinum toxin type A
- Where
- 17 sites in Czechia, France and 3 more
- Volunteers
- 47 people
- Sponsor
- Ipsen
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease.
- Conditions
- Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma
- Trial name
- NCT00025259
- Testing
- Bleomycin Sulfate, Cisplatin, Cyclophosphamide
- Where
- 175 sites in United States, Australia and 5 more
- Volunteers
- 1,734 people
- Sponsor
- Children's Oncology Group
Relapsing Remitting Multiple Sclerosis
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
The aim of this study is to study the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for 6 months on immune system and Th1/Th2 balance in patients with Multiple…
- Trial name
- NCT01225289
- Testing
- Vitamin A
- Where
- 2 sites in Iran
- Volunteers
- 36 people
- Sponsor
- Tehran University of Medical Sciences
Multiple Sclerosis
An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An open-label extension study in which patients with multiple sclerosis received GW-1000-02 [named Sativex® in Canada and also named Sativex® Oromucosal Spray] for four weeks in an open-label manner.
- Trial name
- NCT01610713
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 154 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple…
- Trial name
- CLOCK-MS (NCT03963375)
- Testing
- Cladribine
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Gregory Wu
Radiologically Isolated Syndrome, Multiple Sclerosis
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
This is a multicenter, randomized, double-blind, placebo-controlled, Phase 4 study in which eligible patients with RADIOLOGICALLY ISOLATED SYNDROME (RIS) (as defined by meeting 2017 McDonald criteria for DIS) will be randomized…
- Trial name
- CELLO (NCT04877457)
- Testing
- Ocrelizumab
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Amyotrophic Lateral Sclerosis
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month…
- Trial name
- MITOTARGET (NCT00868166)
- Testing
- Olesoxime, Riluzole
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 512 people
- Sponsor
- Hoffmann-La Roche
Non-relapsing Secondary Progressive Multiple Sclerosis
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic…
- Trial name
- HERCULES (NCT04411641)
- Testing
- Tolebrutinib
- Where
- 306 sites in United States, Argentina and 29 more
- Volunteers
- 1,131 people
- Sponsor
- Sanofi
Multiple Sclerosis, Urinary Bladder Diseases
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder…
- Trial name
- NCT01930799
- Testing
- Systematic Screening and Education Regimen
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The…
- Trial name
- NCT00411619
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.